APA (7th ed.) Citation

MS, D., HM, N., A, S., D, B., O, T., T, R., . . . H, T. (2022). Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: A phase 1/2b randomised controlled trial. The Lancet. Infectious diseases, 22(12), 1728. https://doi.org/10.1016/S1473-3099(22)00442-X

Chicago Style (17th ed.) Citation

MS, Datoo, et al. "Efficacy and Immunogenicity of R21/Matrix-M Vaccine Against Clinical Malaria After 2 Years' Follow-up in Children in Burkina Faso: A Phase 1/2b Randomised Controlled Trial." The Lancet. Infectious Diseases 22, no. 12 (2022): 1728. https://doi.org/10.1016/S1473-3099(22)00442-X.

MLA (9th ed.) Citation

MS, Datoo, et al. "Efficacy and Immunogenicity of R21/Matrix-M Vaccine Against Clinical Malaria After 2 Years' Follow-up in Children in Burkina Faso: A Phase 1/2b Randomised Controlled Trial." The Lancet. Infectious Diseases, vol. 22, no. 12, 2022, p. 1728, https://doi.org/10.1016/S1473-3099(22)00442-X.